Serum anti-p53 antibody as a tumour marker for colorectal cancer screening

Abstract

A 60-year-old Japanese man presented to our hospital for further investigation of an elevated serum anti-p53 antibody level. He was diagnosed with colon cancer and the tumour was surgically resected. Histological diagnosis of advanced colon cancer without lymph node involvement or distant metastasis was made. It was noteworthy that both serum carcinoembryonic antigen (CEA) and a fecal occult blood test that were performed preoperatively were non-diagnostic. This case highlights the potential usefulness of serum anti-p53 antibody tests for detection of colorectal cancers. Moreover, sequential changes in the anti-p53 antibody levels after curative resection were observed.

Inducible Nitric Oxide Synthase in the Carcinogenesis of Gastrointestinal Cancers

“…More than 50% of all human tumors have mutations in the tumor suppressor protein p53 and/or proteins that regulate its function (2). p53 status is a common biomarker in clinical studies of cancers, including breast (29), colorectal (72,150), gastric (61), and esophageal cancer (63), as well as other cancers (131). As a tumor suppressor, p53 has multiple roles in cell signaling.…”

Expression and clinicopathologic significance of TUFM and p53 for the normal–adenoma–carcinoma sequence in colorectal epithelia

“…Sui et al reported that p53 could control cell invasion by inhibiting the NF-κB-mediated activation of Fascin [ 27 ]. Serum anti-p53 antibody was proved to be a useful biomarker for colorectal cancer screening [ 28 ]. p53 also plays critical roles in the transition from colorectal adenoma to carcinoma [ 29 ].…”

New Developments of Gastric Cancer Biomarker Research

“…CEA, CA125, CA19-9, AFP, M2 Pyruvate Kinase are common tumor markers also overexpressing in other type of cancers [48][49][50][51][52][53][54]. p53 antibodies usually indicates p53 gene mutations, which also happened in many type of cancers [55]. cytokeratin 18, RegIV are apoptosis related proteins indicating cell death during gastric cancer development [56,57].…”